Drug intelligence / Profile preview

OGD212

Development stage: Preclinical
Lead developer: Cellula Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral, Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Rectal, Vaginal, Intrathecal, Intratumoral

Overview

OGD212 is a preclinical-stage diagnostic agent being developed by OGD2 Pharma. It is designed to serve as a biomarker for solid tumors by targeting O-acetylated GD2 (OAcGD2). OAcGD2 is a tumor-associated ganglioside that is expressed in various cancers, such as neuroblastoma and melanoma, but is notably absent from normal tissues, including peripheral nerves—a key distinction from the related GD2 ganglioside. OGD212 is intended to facilitate patient selection and monitoring for OAcGD2-targeted therapies, potentially improving the precision of treatment for OAcGD2-positive malignancies.

Targets

OAcGD2 (O-acetyl-GD2)

Beyond the preview

Go deeper on OGD212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OGD212.

Explore the full profile